Status:
COMPLETED
A Retrospective, Observational Study of RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
This retrospective, multi-centre, observational study will assess the daily practice patterns and outcomes of the management of rheumatoid arthritis in patients treated with RoActemra/Actemra (tociliz...
Eligibility Criteria
Inclusion
- Adult patients, \>=18 years of age
- Diagnosed with rheumatoid arthritis and moderate to severe disease activity defined as a DAS28 \>=5.1
- Inadequate responder to at least 2 non-biological DMARDs
- Absence of documented erosions at start of RoActemra/Actemra treatment
- Received RoActemra/Actemra treatment for at least 6 months
- Availability of data from at least the RoActemra/Actemra treatment initiation visit and the 6 months visit
Exclusion
- Contraindications for treatment with RoActemra/Actemra
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT01921478
Start Date
August 1 2010
End Date
November 1 2010
Last Update
August 13 2013
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Aalst, Belgium, 9300
2
Antwerp, Belgium, 2020
3
Bruges, Belgium, 8000
4
Brussels, Belgium, 1020